Literature DB >> 33660330

Safe use of right lobe living donor livers with moderate steatosis in adult-to-adult living donor liver transplantation: a retrospective study.

Young-In Yoon1, Gi-Won Song1, Sung-Gyu Lee1, Gil-Chun Park1, Shin Hwang1, Ki-Hun Kim1, Chul-Soo Ahn1, Deok-Bog Moon1, Tae-Yong Ha1, Dong-Hwan Jung1, Kyung-Won Kim2, Ju-Hyun Shim3, Eun-Young Tak4, Varvara A Kirchner5, Timothy L Pruett5.   

Abstract

Hepatic steatosis (HS) beyond a certain degree can jeopardize living donor (LD) safety, particularly in right lobe (RL) donors, making it a major obstacle for donor pool expansion in adult-to-adult living donor liver transplantation (ALDLT). From July 2004 to June 2016, 58 LDs donated their RLs despite having moderate HS (30%-50% steatosis) determined by intraoperative biopsy at a single center. We performed greedy matching to compare the outcomes of the donors and recipients of this group with those of LDs with no HS. The mean left lobe (LL) HS value in the 58 cases was 20.9 ± 12.4%, which was significantly lower than the mean RL HS value (38.8 ± 6.7%, P < 0.001). The mean ratio of the remnant LL to the total liver volume was 37.8 ± 2.2. No differences were observed in the postoperative liver function and donor and recipient morbidity and mortality rates. The liver regeneration rates in recipients and donors at 1 month, 6 months, and 1 year postoperatively did not differ significantly. The patient and graft survival rates of the recipients showed no differences. The use of well-selected RL grafts with moderate steatosis does not impair graft function, recipient outcomes, or donor safety.
© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatic steatosis; living donor liver transplantation; right lobe donation

Year:  2021        PMID: 33660330     DOI: 10.1111/tri.13859

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  1 in total

1.  Learning Curve of Ex Vivo Liver Resection and Autotransplantation in Treating End-Stage Hepatic Alveolar Echinococcosis: A RA-CUSUM Analysis.

Authors:  Yiwen Qiu; Xianwei Yang; Tao Wang; Shu Shen; Yi Yang; Bin Huang; Wentao Wang
Journal:  Front Surg       Date:  2021-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.